REQUEST A DEMO
Total
USD $0.00
Search more companies

Scigen Pte. Ltd. (Singapore)

Main Activities: Pharmaceutical and Medicine Manufacturing
Full name: Scigen Pte. Ltd. Profile Updated: March 29, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2022 Available in: English Download a sample report

Scigen Limited is engaged in developing, manufacturing, and marketing recombinant human health care biotechnology derived products including human growth hormone, human insulin and human GCSF. The company focuses in the areas of endocrinology, gastroenterology and immunology. Scigen Limited is headquartered in Singapore with in Australia, China, India, Korea, Philippines and Vietnam, partners and distributors in all other countries. The company operates as a subsidiary of Bioton S.A.

Headquarters
150 Beach Road, #32-05/08 Gateway West, Singapore
Singapore; Singapore; Postal Code: 189720

Contact Details: Purchase the Scigen Pte. Ltd. report to view the information.

Basic Information
Outstanding Shares:
Purchase the Scigen Pte. Ltd. report to view the information.
Financial Auditors:
Purchase the Scigen Pte. Ltd. report to view the information.
Incorporation Date:
November 25, 1998
Key Executives
Purchase this report to view the information.
Director
Purchase this report to view the information.
Director
Purchase this report to view the information.
Director
Purchase this report to view the information.
Company Secretary
Ownership Details
Purchase this report to view the information.
100%
Company Performance
Financial values in the chart are available after Scigen Pte. Ltd. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency USD. Absolute financial data is included in the purchased report.
Net sales revenue
17.5%
Total operating revenue
17.5%
Net Profit (Loss) for the Period
N/A
Total assets
1.18%
Total equity
-0.27%
Net Profit Margin
N/A
Return on Equity (ROE)
N/A

Related EMIS Industry Reports

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?